GlaxoSmithKline announces approval of ARRANON injection (GSK) 52.37 +1.03:Co announces FDA has approved ARRANON (nelarabine) Injection, a chemotherapy agent, for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.